Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
about
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapyThe discovery and development of selective estrogen receptor modulators (SERMs) for clinical practiceTamoxifen regulation of sphingolipid metabolism--Therapeutic implicationsStructural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.Opportunities to minimise risk in drug discovery and development.Ligand dissociation from estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulationsAn alternative conformation of ERβ bound to estradiol reveals H12 in a stable antagonist positionDiscovering small-molecule estrogen receptor α/coactivator binding inhibitors: high-throughput screening, ligand development, and models for enhanced potency.Discovery and total synthesis of a new estrogen receptor heterodimerizing actinopolymorphol A from Actinopolymorpha rutilusEstrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential.2-Amino-7-oxo-4,5,6,7-tetra-hydro-1-benzothio-phene-3-carbonitrile.Estrogen receptor ligands: a patent review update.Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Estrogen receptor β ligands: recent advances and biomedical applications.Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs.Synthesis and evaluation of 17α-E-20-(heteroaryl)norpregn-1,3,5(10),20 tetraene-3,17β-diols [17α-(heteroaryl)vinyl estradiols] as ligands for the estrogen receptor-α ligand binding domain (ERα-LBD).The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.Hydrophobic Interactions Improve Selectivity to ERα for Ben-zothiophene SERMs.Single and multiple ascending dose studies of a novel tissue-selective oestrogen receptor modulator, CHF 4227, in healthy postmenopausal women.Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects.Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure-activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides.Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds.The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.Synthesis and evaluation of 11β-(4-substituted phenyl) estradiol analogs: transition from estrogen receptor agonists to antagonists.Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.Nonsteroidal bivalent estrogen ligands: an application of the bivalent concept to the estrogen receptor.Ligand structure-dependent activation of estrogen receptor alpha/Sp by estrogens and xenoestrogens.New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.In vivo profiling of estrogen receptor/specificity protein-dependent transactivation.Selective estrogen receptor modulators and phytoestrogens.Copper triflate-mediated synthesis of 1,3,5-triarylpyrazoles in [bmim][PF6] ionic liquid and evaluation of their anticancer activitiesEstrogen Receptor Ligands: A Review (2013-2015).Crystal structure of 6-(p-tol-yl)benzo[b]naphtho[2,3-d]thio-phene and of an ortho-rhom-bic polymorph of 7-phenyl-anthra[2,3-b]benzo[d]thio-phene.Minireview: role of orphan nuclear receptors in cancer and potential as drug targetsThe selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats.17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review.Prenylated isoflavonoids from plants as selective estrogen receptor modulators (phytoSERMs).Ferrocenyl catechols: synthesis, oxidation chemistry and anti-proliferative effects on MDA-MB-231 breast cancer cells.
P2860
Q24803990-B06453EC-9D52-4091-AFF2-8D5C7B5A1024Q26830744-E85C9362-5405-4B10-9674-B92FA63A2F98Q28084270-A2C1F5F5-A8DD-4A34-9A48-F8289D785916Q30418832-8F0F0583-303F-4B2D-B539-D32EE08A46AEQ30428283-4A5C6553-BE12-4CFD-A6BA-5ACA81E72A5AQ33642693-351316B7-B240-49FC-A916-9E830F6BA8D0Q33799630-F903C784-F0FA-4425-8EDE-EB82C66134F1Q33834493-814C3DC8-63E3-4FF7-B310-B63FC2DBA0EDQ34033102-5EA89FD4-B9EE-4CF2-92B4-751A9911ADB7Q34315419-11971FED-CBFB-4446-85E7-60F22F806705Q34317728-394C4198-0AD4-43D9-B828-389B10269D7DQ34347152-3D17AC38-7043-4A43-A0D5-F9E0662159A6Q34652138-F02810F4-CF32-4963-8AA8-97C4F8F27E09Q34736075-B203C766-6D82-44F9-B67E-342CC323652BQ35016384-A647A9E5-0330-4A4B-8883-993A3D9EA3BCQ35023715-78647741-B780-400D-8A5A-F8AF2D5EEE64Q35620990-4289DA16-7913-4347-9691-7C69FF24DC86Q35676299-7B403189-D12E-4FDB-9960-CA8A39C83FDDQ35827822-2EABDCD7-DF54-4E55-AF67-620896DB04F3Q35949610-47890ED7-E876-4FB5-8248-DEAB38535698Q36024730-0C982071-371D-444B-9B49-0234B4FF9F43Q36364465-81B1D17B-150D-44C7-B441-7A9E00091547Q36405734-C55F73E5-1BD0-41C4-A970-B9D6EB800C03Q36427475-97596F53-F860-4EDF-A068-7EF4D84F1C8EQ36598699-B214D73A-E6E0-4123-88C3-E49B2561FC84Q36635650-1C0FAF7A-065D-4612-89AF-821CACE39085Q36684234-CDCDB81B-BEAA-42FD-B5F2-400EDFDADDBBQ36781304-8EA7BF80-BD07-4C5C-8A9D-CF12EE07B4FCQ36844748-6AC7CF3F-F4D2-4896-A561-CFAC17E604E2Q36927087-2891EF20-B2D3-4026-BEB3-108346D63854Q36976420-69401DD0-DD9D-4AC6-810E-031C7C727430Q36984515-9457DAF2-18F1-4A7E-BD02-1B3F46FA7C73Q37249742-474E48C2-BD6F-41E4-83C1-1C497DA0509FQ37339491-17C2109A-241D-4406-BB93-8550CCB46BA9Q37432486-8B03BC05-862D-4445-B7C5-21F72B11AE9FQ37496691-124EC2CC-FE7F-427D-AD3A-351B56C05C5AQ37583723-13AF801A-908B-4331-929F-E6E17BAB7287Q37774374-3ED9A6C2-8BB9-4309-8CDA-722203E21570Q38017574-6A346DBF-AECB-4E87-915D-11F064495805Q39346477-EB5C2F31-A496-45AB-B089-79FD1273D391
P2860
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Antiestrogens and selective es ...... considerations and new agents.
@ast
Antiestrogens and selective es ...... considerations and new agents.
@en
Antiestrogens and selective es ...... considerations and new agents.
@nl
type
label
Antiestrogens and selective es ...... considerations and new agents.
@ast
Antiestrogens and selective es ...... considerations and new agents.
@en
Antiestrogens and selective es ...... considerations and new agents.
@nl
prefLabel
Antiestrogens and selective es ...... considerations and new agents.
@ast
Antiestrogens and selective es ...... considerations and new agents.
@en
Antiestrogens and selective es ...... considerations and new agents.
@nl
P356
P1476
Antiestrogens and selective es ...... considerations and new agents.
@en
P2093
V Craig Jordan
P304
P356
10.1021/JM020450X
P407
P577
2003-03-01T00:00:00Z